Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business, Merger Agreement, Basis of Presentation, Reclassifications, Reverse Stock Split, and Business Disposals (Details)

Organization, Description of Business, Merger Agreement, Basis of Presentation, Reclassifications, Reverse Stock Split, and Business Disposals (Details)				3 Months Ended		9 Months Ended
	Oct. 24, 2019 USD ($)	Jul. 15, 2019 USD ($)	Jul. 05, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares	Sep. 30, 2019 USD ($)	Dec. 31, 2020	Aug. 24, 2020 $ / shares	Dec. 31, 2019 USD ($) $ / shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common stock, par value (usd per share) \| $ / shares				$ 0.0001		$ 0.0001			$ 0.0001	$ 0.0001
Reverse stock split, conversion ratio	30
Excess consideration note matured amount	$ 6,000,000.0
Interest paid				$ 0	$ 38,000	$ 0	$ 2,211,000
Earn-Out from siParadigm, net, current portion				141,000		141,000				$ 747,000
StemoniX \| Cancer Genetics, Inc. \| Subsequent Event \| Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership percentage, parent								78.00%
Existing stockholders of CGI \| Cancer Genetics, Inc. \| Subsequent Event \| Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Ownership percentage, noncontrolling owners								22.00%
BioPharma Disposal
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gross consideration	$ 153,000	$ 23,500,000
Closing adjustments		2,000,000.0
Promissory note receivable		7,700,000
Cash received from transaction		$ 2,300,000
Interest rate	6.00%
Interest paid	$ 24,000
Net worth adjustment	775,000
Security for indemnification obligations	$ 735,000
PFG \| Secured Debt
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Term note, principal balance				6,000,000.0		6,000,000.0
Buyer
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Due to affiliate, current				421,000		421,000				$ 0
Clinical Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash consideration received, total			$ 747,000
Cash consideration received for equipment			45,000
Payments on Advance from NovellusDx, Ltd.			1,000,000.0
Supplier invoices paid directly to related party			$ 298,000
Term of contract			24 months
Period of service			12 months
Non-compete term			3 years
Transition Services Agreement \| BioPharma Disposal
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Related party shares services				10,000		208,000
Transition Services Agreement, Reimbursement of Salaries and Benefits \| BioPharma Disposal
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Related party shares services				$ 5,000		$ 155,000
Discontinuing Operations \| Convertible Note
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest expense, debt					$ 22,000		$ 1,500,000